Page last updated on July 16, 2024
Inmune Bio, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-28 16:06:15 EDT.
Filings
10-K filed on 2024-03-28
Inmune Bio, Inc. filed a 10-K at 2024-03-28 16:06:15 EDT
Accession Number: 0001213900-24-027206
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
ITEM 1C. CYBERSECURITY Risk Management and Strategy We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to help protect our Company from cyber threats as well as secure our networks and systems. Such processes include safeguards, response plan, and review of our policies and procedures to identify risks. We engage an external party to enhance our cybersecurity oversight. Governance Our Audit Committee of the Board of Directors, or the Audit Committee, is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters, and is notified between such updates regarding any significant new cybersecurity threats or incidents. We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. Our Chief Financial Officer is responsible for the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks.
Company Information
Name | Inmune Bio, Inc. |
CIK | 0001711754 |
SIC Description | Biological Products, (No Diagnostic Substances) |
Ticker | INMB - Nasdaq |
Website | |
Category | Emerging growth company |
Fiscal Year End | December 30 |